These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15375317)

  • 1. Suppression of pancreatic and colon cancer cells by antisense K-ras RNA expression vectors.
    Aoki K; Ohnami S; Yoshida T
    Methods Mol Med; 2005; 106():193-204. PubMed ID: 15375317
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
    Nakano M; Aoki K; Matsumoto N; Ohnami S; Hatanaka K; Hibi T; Terada M; Yoshida T
    Mol Ther; 2001 Apr; 3(4):491-9. PubMed ID: 11319909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.
    Hatanaka K; Suzuki K; Miura Y; Yoshida K; Ohnami S; Kitade Y; Yoshida T; Aoki K
    J Gene Med; 2004 Oct; 6(10):1139-48. PubMed ID: 15452878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotide treatment of ras-induced tumors in nude mice.
    Wickstrom E
    Mol Biotechnol; 2001 May; 18(1):35-55. PubMed ID: 11439698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.
    Shi XH; Liang ZY; Ren XY; Liu TH
    Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity.
    Aoki K; Yoshida T; Sugimura T; Terada M
    Cancer Res; 1995 Sep; 55(17):3810-6. PubMed ID: 7641198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
    Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
    Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transduction effect of antisense K-ras on malignant phenotypes in gastric cancer cells.
    Song JJ; Lee H; Kim E; Kim YS; Yoo NC; Roh JK; Kim BS; Kim J
    Cancer Lett; 2000 Aug; 157(1):1-7. PubMed ID: 10893435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer.
    Xing HR; Cordon-Cardo C; Deng X; Tong W; Campodonico L; Fuks Z; Kolesnick R
    Nat Med; 2003 Oct; 9(10):1266-8. PubMed ID: 12960962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
    Ohnami S; Matsumoto N; Nakano M; Aoki K; Nagasaki K; Sugimura T; Terada M; Yoshida T
    Cancer Res; 1999 Nov; 59(21):5565-71. PubMed ID: 10554036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides and the rational design of new antitumor drugs.
    Prieto J; Hernández-Alcoceba R
    Rev Esp Enferm Dig; 2005 Jul; 97(7):467-71. PubMed ID: 16262525
    [No Abstract]   [Full Text] [Related]  

  • 12. [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells].
    Shen YM; Yang XC; Zhang MH; Shen JK; Sun YH
    Ai Zheng; 2008 May; 27(5):496-504. PubMed ID: 18479599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy of pancreatic cancer targeting the K-Ras oncogene.
    Lisiansky V; Naumov I; Shapira S; Kazanov D; Starr A; Arber N; Kraus S
    Cancer Gene Ther; 2012 Dec; 19(12):862-9. PubMed ID: 23099885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
    Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
    Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
    Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A homologous promoterless K-ras cDNA targeting endogenous K-ras expression inhibits human pancreatic cancer cell growth in vitro and in vivo.
    Ren XY; Liang ZY; Shi XH; Liu TH
    Cancer Biol Ther; 2008 Oct; 7(10):1641-7. PubMed ID: 18769120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis.
    Fong S; Itahana Y; Sumida T; Singh J; Coppe JP; Liu Y; Richards PC; Bennington JL; Lee NM; Debs RJ; Desprez PY
    Proc Natl Acad Sci U S A; 2003 Nov; 100(23):13543-8. PubMed ID: 14578451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitary effects of antisense oligonucleotide specific to K-ras point mutation on the target gene expression in human pancreatic carcinoma cells.
    Wang YX; Gao L; Ji ZZ
    Chin Med J (Engl); 2007 Aug; 120(16):1448-50. PubMed ID: 17825176
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.